ANTIDIABETIC SGLT-2 INHIBITOR MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-165233 | Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Antidiabetic Sglt-2 Inhibitor Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL ANTIDIABETIC SGLT-2 INHIBITOR MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL ANTIDIABETIC SGLT-2 INHIBITOR MARKET
7.1 GLOBAL ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA ANTIDIABETIC SGLT-2 INHIBITOR MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Novo Nordisk
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Border Valley
16.3 Pfizer
16.4 Sanofi
16.5 AstraZeneca
16.6 Eli Lilly
16.7 Bristol-Myers Squibb
16.8 Merck & Co
16.9 Johnson & Johnson
16.10 Boehringer Ingelheim
16.11 Takeda Pharmaceuticals
16.12 Anderson Hay & Grain Inc
16.13 GlaxoSmithKline
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeCanagliflozin
Empagliflozin
Dapagliflozin
By Application
Hospital
Clinic
Companies
Novo Nordisk
Border Valley
Pfizer
Sanofi
AstraZeneca
Eli Lilly
Bristol-Myers Squibb
Merck & Co
Johnson & Johnson
Boehringer Ingelheim
Takeda Pharmaceuticals
Anderson Hay & Grain Inc
GlaxoSmithKline
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.